Biomedical Research Career Programme Phase III approved by Union Cabinet in 2025, supporting 2,000 researchers, enhancing interdisciplinary research, and empowering women in science.
Cabinet Approves Phase III of Biomedical Research Career Programme (BRCP)
On October 1, 2025, the Union Cabinet, chaired by Prime Minister Narendra Modi, approved the third phase of the Biomedical Research Career Programme (BRCP). This phase is set to run from 2025–26 to 2030–31, with an additional six-year extension until 2037–38 to continue supporting fellowships and grants approved until 2030–31. The programme will be implemented in partnership between the Department of Biotechnology (DBT), Government of India, and the Wellcome Trust, UK, through the India Alliance. The total financial outlay for Phase III is ₹1,500 crore, with DBT contributing ₹1,000 crore and the Wellcome Trust contributing ₹500 crore
Objectives and Key Components
Phase III of BRCP aims to nurture top-tier scientific talent for cutting-edge biomedical research and promote interdisciplinary research for translational innovation. The programme will strengthen systems supporting high-quality research and reduce regional disparities in scientific capacity to create world-class biomedical research capacity with global impact. The key components of Phase III include:
- Early Career and Intermediate Research Fellowships: These fellowships are globally recognized and tailored for the formative stages of a scientist’s research career in basic, clinical, and public health sciences.
- Collaborative Grants Programme: This includes Career Development Grants and Catalytic Collaborative Grants for 2-3 investigator teams for early and mid-senior career researchers, respectively, with strong research track records in India.
- Research Management Programme: This programme aims to strengthen core research endeavours and enhance research capabilities across India.
Additionally, Phase III will focus on strengthening mentorship, networking, public engagement, and developing new and innovative national and international partnerships. The programme is expected to train over 2,000 students and postdoctoral fellows, generate high-impact publications, enable patentable discoveries, and increase support for women in science. It also aims to expand activities and engagement in Tier-2/3 settings.
Why This News Is Important
Advancement of Biomedical Research in India
The approval of Phase III of BRCP signifies a significant step towards enhancing India’s capabilities in biomedical research. By investing in early and intermediate career fellowships, collaborative grants, and research management programmes, the government aims to foster a robust research ecosystem that can address the country’s health challenges and contribute to global scientific advancements.
Empowerment of Women in Science
One of the key objectives of Phase III is to increase support for women in science. The programme aims to enable a 10–15% increase in support to women, thereby promoting gender equality in the scientific community and encouraging more women to pursue and sustain careers in biomedical research.
Reduction of Regional Disparities
The programme’s pan-India implementation strategy focuses on reducing regional disparities in scientific capacity. By engaging Tier-2/3 settings, BRCP aims to decentralize research activities and ensure that high-quality research opportunities are accessible across the country, thereby promoting inclusive growth in the scientific sector.
Enhancement of Translational Research
Phase III emphasizes translational innovation, aiming to bridge the gap between laboratory research and its application in public health. By promoting interdisciplinary research and collaborative grants, the programme seeks to facilitate the development of solutions that can directly impact public health outcomes.
Alignment with National and Global Priorities
The launch of Phase III aligns with India’s goals of fostering skills and innovation under the “Viksit Bharat” initiative. By investing in biomedical research, the government aims to position India as a global leader in scientific research and innovation, contributing to the nation’s development and global scientific community.
Historical Context
The Biomedical Research Career Programme (BRCP) was launched in 2008–09 by the Department of Biotechnology in partnership with the Wellcome Trust, UK, through the DBT/Wellcome Trust India Alliance. The programme was established to offer research fellowships based in India for biomedical research at world-class standards. Phase II was implemented in 2018/19 with an expanded portfolio, building upon the successes of Phase I. Phase III aims to further strengthen India’s biomedical research capabilities and align with national priorities and global benchmarks.
Key Takeaways from “Cabinet Approves Phase III of Biomedical Research Career Programme”
| S.No | Key Takeaway |
|---|---|
| 1 | Financial Outlay: ₹1,500 crore allocated for Phase III of BRCP. |
| 2 | Implementation Period: 2025–26 to 2030–31, with extension until 2037–38. |
| 3 | Partnership: Collaboration between DBT, Wellcome Trust, and India Alliance. |
| 4 | Key Components: Early Career Fellowships, Collaborative Grants, Research Management Programme. |
| 5 | Expected Outcomes: Training over 2,000 researchers, generating high-impact publications, enabling patentable discoveries, increasing support for women in science, and expanding activities in Tier-2/3 settings. |
FAQs: Frequently Asked Questions
1. What is the Biomedical Research Career Programme (BRCP)?
The BRCP is a government initiative by the Department of Biotechnology (DBT) in partnership with the Wellcome Trust, UK, through the India Alliance. It aims to support biomedical research in India by providing fellowships, grants, and mentorship for scientists at various career stages.
2. When was Phase III of BRCP approved and what is its duration?
Phase III was approved on October 1, 2025, and will run from 2025–26 to 2030–31, with a six-year extension until 2037–38 for ongoing fellowships and grants.
3. What is the financial allocation for Phase III of BRCP?
The total financial outlay is ₹1,500 crore, with ₹1,000 crore contributed by DBT and ₹500 crore by the Wellcome Trust, UK.
4. What are the main objectives of Phase III?
Phase III aims to nurture top-tier scientific talent, promote interdisciplinary research, strengthen research systems, reduce regional disparities, and support women in science.
5. How many students and postdoctoral fellows are expected to benefit from Phase III?
The programme is expected to train over 2,000 students and postdoctoral fellows across India.
6. Which key components are included in Phase III of BRCP?
Key components include Early Career and Intermediate Research Fellowships, Collaborative Grants Programmes (Career Development and Catalytic Collaborative Grants), and the Research Management Programme.
7. How does BRCP Phase III support women in science?
Phase III focuses on increasing support for women researchers by 10–15%, promoting gender equality and encouraging sustained careers in biomedical research.
8. How will BRCP Phase III reduce regional disparities?
The programme includes activities in Tier-2 and Tier-3 settings, ensuring that high-quality research opportunities are accessible across India.
9. What kind of research impact is expected from Phase III?
Phase III is expected to generate high-impact publications, facilitate patentable discoveries, enhance translational research, and strengthen India’s biomedical research capacity.
10. Which organizations are implementing Phase III of BRCP?
It is implemented jointly by the Department of Biotechnology (DBT), India, and the Wellcome Trust, UK, through the India Alliance.
Some Important Current Affairs Links
